MDR 001
Alternative Names: MDR-001; MRANK-001Latest Information Update: 04 Oct 2026
At a glance
- Originator MindRank
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2026 MindRank enters into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical and Zhejiang Wansheng Pharmaceutical (both subsidiaries of 3SBio) for MDR 001
- 28 Jul 2026 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (PO)
- 08 Jun 2026 Efficacy and adverse events data from a phase IIb trial in Obesity presented at the 86th Annual Scientific Sessions of the American Diabetes Association (ADA-2026)